Trial
NCT00276159
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
Pfizer
Condition
Acute Lymphoblastic Leukemia
Intervention
852A
Why stopped
Drug was not available.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-04